Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.35 |
| ▸ | HTR6 | P50406 | 3/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17458503 | 1.00 | TRPA1 (0.35) | TRPA1HTR6PTGDR2SCN9AROCK2 | |
| SCHEMBL17467761 | 1.00 | TRPA1 (0.35) | TRPA1HTR6PTGDR2SCN9AROCK2 | |
| SCHEMBL17467779 | 1.00 | TRPA1 (0.35) | TRPA1HTR6PTGDR2SCN9AROCK2 | |
| SCHEMBL17464730 | 1.00 | TRPA1 (0.35) | TRPA1HTR6PTGDR2SCN9AROCK2 | |
| SCHEMBL17458516 | 1.00 | TRPA1 (0.35) | TRPA1HTR6PTGDR2SCN9AROCK2 | |
| SCHEMBL17458581 | 1.00 | TRPA1 (0.35) | TRPA1HTR6PTGDR2SCN9AROCK2 | |
| SCHEMBL17467824 | 0.92 | KDM1A (0.38) | HTR6PTGDR2GRM2HRH3 | |
| SCHEMBL17458565 | 0.92 | KDM1A (0.38) | HTR6PTGDR2GRM2HRH3 | |
| SCHEMBL17464772 | 0.92 | KDM1A (0.38) | HTR6PTGDR2GRM2HRH3 | |
| SCHEMBL17458585 | 0.92 | KDM1A (0.38) | HTR6PTGDR2GRM2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701663-B2 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RARA, RARB, RXRA | TRPA1 1807/4885HTR6 2847/4885PTGDR2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.